Publication

Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease

van Haaften, W. T., Mortensen, J. H., Karsdal, M. A., Bay-Jensen, A. C., Dijkstra, G. & Olinga, P., Jul-2017, In : Alimentary Pharmacology & Therapeutics. 46, 1, p. 26-39 14 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van Haaften, W. T., Mortensen, J. H., Karsdal, M. A., Bay-Jensen, A. C., Dijkstra, G., & Olinga, P. (2017). Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease. Alimentary Pharmacology & Therapeutics, 46(1), 26-39. https://doi.org/10.1111/apt.14092

Author

van Haaften, W. T. ; Mortensen, J. H. ; Karsdal, M. A. ; Bay-Jensen, A. C. ; Dijkstra, G. ; Olinga, P. / Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease. In: Alimentary Pharmacology & Therapeutics. 2017 ; Vol. 46, No. 1. pp. 26-39.

Harvard

van Haaften, WT, Mortensen, JH, Karsdal, MA, Bay-Jensen, AC, Dijkstra, G & Olinga, P 2017, 'Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease', Alimentary Pharmacology & Therapeutics, vol. 46, no. 1, pp. 26-39. https://doi.org/10.1111/apt.14092

Standard

Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease. / van Haaften, W. T.; Mortensen, J. H.; Karsdal, M. A.; Bay-Jensen, A. C.; Dijkstra, G.; Olinga, P.

In: Alimentary Pharmacology & Therapeutics, Vol. 46, No. 1, 07.2017, p. 26-39.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van Haaften WT, Mortensen JH, Karsdal MA, Bay-Jensen AC, Dijkstra G, Olinga P. Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease. Alimentary Pharmacology & Therapeutics. 2017 Jul;46(1):26-39. https://doi.org/10.1111/apt.14092


BibTeX

@article{b64ddbd95ecb41deb34b38232ccbf1b9,
title = "Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease",
abstract = "Background: Misbalances in extracellular matrix turnover are key factors in the development of stricturing (Montreal B2) and penetrating (Montreal B3) Crohn's disease.Aim: To determine whether serological markers for collagen formation and degradation could serve as biomarkers for complications of Crohn's disease.Methods: Serum biomarkers for type I, III, V and VI collagen formation (P1NP, ProC3, Pro-C5, Pro-C6) and matrix metalloproteinase mediated degradation (C1M, C3M, C5M and C6M) were measured in a retrospective, single centre cohort of 112 patients with Crohn's disease in the terminal ileum (nonstricturing/nonpenetrating: n=40, stricturing: n=55, penetrating: n=17) and 24 healthy controls. Active inflammation was defined as CRP >5 mg/L.Results: C3M and Pro-C5 levels were higher in penetrating vs nonpenetrating/nonstricturing and stricturing disease (33.6 +/- 5 vs 25.8 +/- 2.2 [P=.004] and 27.2 +/- 2.3 [P=.018] nmol/L C3M, 1262.7 +/- 259.4 vs 902.9 +/- 109.9 [P=.005] and 953.0 +/- 106.4 [P=.015]nmol/L Pro-C5). C1M (71.2 +/- 26.1 vs 46.2 +/- 6.2 nmol/L [PConclusions: Serological biomarkers show that penetrating Crohn's disease is characterised by increased matrix metalloproteinase-9 degraded type III collagen and formation of type V collagen. Active inflammation in Crohn's disease is characterised by increased formation of type V collagen and increased matrix metalloproteinase mediated breakdown of type I, III collagen. Pro-C3/C3M-ratios are superior in differentiating between penetrating Crohn's disease vs inflammatory and stricturing Crohn's disease.",
keywords = "INFLAMMATORY-BOWEL-DISEASE, MATRIX METALLOPROTEINASES, NOD2/CARD15 GENOTYPE, INTESTINAL FIBROSIS, LIVER, LOCATION, FISTULAS, BEHAVIOR, SURGERY, MARKER",
author = "{van Haaften}, {W. T.} and Mortensen, {J. H.} and Karsdal, {M. A.} and Bay-Jensen, {A. C.} and G. Dijkstra and P. Olinga",
year = "2017",
month = "7",
doi = "10.1111/apt.14092",
language = "English",
volume = "46",
pages = "26--39",
journal = "Alimentary Pharmacology & Therapeutics",
issn = "0269-2813",
publisher = "Wiley",
number = "1",

}

RIS

TY - JOUR

T1 - Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease

AU - van Haaften, W. T.

AU - Mortensen, J. H.

AU - Karsdal, M. A.

AU - Bay-Jensen, A. C.

AU - Dijkstra, G.

AU - Olinga, P.

PY - 2017/7

Y1 - 2017/7

N2 - Background: Misbalances in extracellular matrix turnover are key factors in the development of stricturing (Montreal B2) and penetrating (Montreal B3) Crohn's disease.Aim: To determine whether serological markers for collagen formation and degradation could serve as biomarkers for complications of Crohn's disease.Methods: Serum biomarkers for type I, III, V and VI collagen formation (P1NP, ProC3, Pro-C5, Pro-C6) and matrix metalloproteinase mediated degradation (C1M, C3M, C5M and C6M) were measured in a retrospective, single centre cohort of 112 patients with Crohn's disease in the terminal ileum (nonstricturing/nonpenetrating: n=40, stricturing: n=55, penetrating: n=17) and 24 healthy controls. Active inflammation was defined as CRP >5 mg/L.Results: C3M and Pro-C5 levels were higher in penetrating vs nonpenetrating/nonstricturing and stricturing disease (33.6 +/- 5 vs 25.8 +/- 2.2 [P=.004] and 27.2 +/- 2.3 [P=.018] nmol/L C3M, 1262.7 +/- 259.4 vs 902.9 +/- 109.9 [P=.005] and 953.0 +/- 106.4 [P=.015]nmol/L Pro-C5). C1M (71.2 +/- 26.1 vs 46.2 +/- 6.2 nmol/L [PConclusions: Serological biomarkers show that penetrating Crohn's disease is characterised by increased matrix metalloproteinase-9 degraded type III collagen and formation of type V collagen. Active inflammation in Crohn's disease is characterised by increased formation of type V collagen and increased matrix metalloproteinase mediated breakdown of type I, III collagen. Pro-C3/C3M-ratios are superior in differentiating between penetrating Crohn's disease vs inflammatory and stricturing Crohn's disease.

AB - Background: Misbalances in extracellular matrix turnover are key factors in the development of stricturing (Montreal B2) and penetrating (Montreal B3) Crohn's disease.Aim: To determine whether serological markers for collagen formation and degradation could serve as biomarkers for complications of Crohn's disease.Methods: Serum biomarkers for type I, III, V and VI collagen formation (P1NP, ProC3, Pro-C5, Pro-C6) and matrix metalloproteinase mediated degradation (C1M, C3M, C5M and C6M) were measured in a retrospective, single centre cohort of 112 patients with Crohn's disease in the terminal ileum (nonstricturing/nonpenetrating: n=40, stricturing: n=55, penetrating: n=17) and 24 healthy controls. Active inflammation was defined as CRP >5 mg/L.Results: C3M and Pro-C5 levels were higher in penetrating vs nonpenetrating/nonstricturing and stricturing disease (33.6 +/- 5 vs 25.8 +/- 2.2 [P=.004] and 27.2 +/- 2.3 [P=.018] nmol/L C3M, 1262.7 +/- 259.4 vs 902.9 +/- 109.9 [P=.005] and 953.0 +/- 106.4 [P=.015]nmol/L Pro-C5). C1M (71.2 +/- 26.1 vs 46.2 +/- 6.2 nmol/L [PConclusions: Serological biomarkers show that penetrating Crohn's disease is characterised by increased matrix metalloproteinase-9 degraded type III collagen and formation of type V collagen. Active inflammation in Crohn's disease is characterised by increased formation of type V collagen and increased matrix metalloproteinase mediated breakdown of type I, III collagen. Pro-C3/C3M-ratios are superior in differentiating between penetrating Crohn's disease vs inflammatory and stricturing Crohn's disease.

KW - INFLAMMATORY-BOWEL-DISEASE

KW - MATRIX METALLOPROTEINASES

KW - NOD2/CARD15 GENOTYPE

KW - INTESTINAL FIBROSIS

KW - LIVER

KW - LOCATION

KW - FISTULAS

KW - BEHAVIOR

KW - SURGERY

KW - MARKER

U2 - 10.1111/apt.14092

DO - 10.1111/apt.14092

M3 - Article

C2 - 28481042

VL - 46

SP - 26

EP - 39

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

SN - 0269-2813

IS - 1

ER -

ID: 46716551